Abstract
To study the utility of the nasal route for the systemic delivery of L-dopa using water soluble prodrugs of L-dopa and to examine if this delivery method will result in preferential delivery to the CNS. Several alkyl ester prodrugs of L-dopa were prepared and their physicochemical properties were determined. In vitro hydrolysis rate constants in buffer, rat plasma, rat brain homogenate, rat CSF, and rat nasal berfusate were determined by HPLC. In vivo nasal experiments were carried out in rats. Levels of L-dopa and dopamine in plasma, CSF, and olfactory bulb were determined using HPLC method with electrochemical detection. All the prodrugs showed improved solubility and lipophilicity with relatively fast in vitro conversion in rat plasma. Absorption was fast following nasal delivery of the prodrugs with bioavailability around 90%. Dopamine plasma levels did not change significantly following nasal administration of the butyl ester prodrug. Olfactory bulb and CSF L-dopa concentration were higher following nasal delivery of the butyl ester prodrug compared to an equivalent intravenous dose. Utilization of water soluble prodrugs of L-dopa via the nasal route in the treatment of Parkinson's disease may have therapeutic advantages such as improved bioavailability, decreased side effects, and potentially enhanced CNS delivery.
MeSH Terms
Administration, Intranasal
Animals
Antiparkinson Agents/administration & dosage,pharmacokinetics
Buffers
Chromatography, High Pressure Liquid
Dopamine/blood
Drug Stability
Half-Life
Hydrolysis
Injections, Intravenous
Levodopa/administration & dosage,analogs & derivatives,pharmacokinetics
Male
Olfactory Bulb/metabolism
Prodrugs/administration & dosage,pharmacokinetics
Rats
Rats, Sprague-Dawley
Solubility
Chemicals
Antiparkinson Agents
Buffers
Prodrugs
Levodopa
Dopamine
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Kao H D
Endo Pharmaceuticals, Garden City, New York 11530, USA.
Traboulsi A
Itoh S
Dittert L
Hussain A
References (25)
25 references, click to expand
-
Improved delivery through biological membranes. 4. Prodrugs of L-dopa.
J Med Chem. 1977 Nov;20(11):1435-45
PMID: 915903
-
High-performance liquid chromatography with amperometric detection of plasma L-3,4-dihydroxyphenylalanine in Parkinsonian patients.
J Chromatogr. 1983 Oct 14;277:115-23
PMID: 6643597
-
Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients.
Neurology. 1986 Jun;36(6):739-44
PMID: 3703280
-
Control of on/off phenomenon by continuous intravenous infusion of levodopa.
Neurology. 1984 Sep;34(9):1131-6
PMID: 6540399
-
Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa.
Arch Neurol. 1988 Aug;45(8):861-4
PMID: 3395259
-
Distribution of antihistamines into the CSF following intranasal delivery.
Biopharm Drug Dispos. 1997 May;18(4):335-46
PMID: 9158881
-
Short-chain alkyl esters of L-dopa as prodrugs for rectal absorption.
Pharm Res. 1989 Jun;6(6):501-5
PMID: 2762226
-
The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug.
Chem Pharm Bull (Tokyo). 1991 Sep;39(9):2456-8
PMID: 1804561
-
Mechanism of nasal absorption of drugs. IV: Plasma levels of radioactivity following intranasal administration of [3H]leucine enkephalin.
J Pharm Sci. 1990 Sep;79(9):768-70
PMID: 2273455
-
Nasal absorption of propranolol from different dosage forms by rats and dogs.
J Pharm Sci. 1980 Dec;69(12):1411-3
PMID: 7463327
-
Mechanism of nasal absorption of drugs I: Physicochemical parameters influencing the rate of in situ nasal absorption of drugs in rats.
J Pharm Sci. 1985 Jun;74(6):608-11
PMID: 4020646
-
Pathogenesis of viral infections of the nervous system.
N Engl J Med. 1968 Jan 4;278(1):23-30 contd
PMID: 4295224
-
A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines.
J Pharmacol Exp Ther. 1962 Dec;138:360-75
PMID: 14013351
-
Clinical pharmacokinetics of anti-parkinsonian drugs.
Clin Pharmacokinet. 1987 Sep;13(3):141-78
PMID: 3311529
-
L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease.
J Pharm Pharmacol. 1987 Aug;39(8):627-35
PMID: 2888854
-
Intranasal drug delivery.
Adv Drug Deliv Rev. 1998 Jan 5;29(1-2):39-49
PMID: 10837579
-
Dosage form design for improvement of bioavailability of levodopa IV: Possible causes of low bioavailability of oral levodopa in dogs.
J Pharm Sci. 1981 Jul;70(7):730-3
PMID: 7264915
-
Dosage form design for improvement of bioavailability of levodopa III: Influence of dose on pharmacokinetic behavior of levodopa in dogs and Parkinsonian patients.
J Pharm Sci. 1980 Dec;69(12):1374-8
PMID: 7463319
-
Dosage form design for improvement of bioavailability of levodopa V: Absorption and metabolism of levodopa in intestinal segments of dogs.
J Pharm Sci. 1981 Oct;70(10):1157-60
PMID: 7299652
-
Experimental investigations on the penetration of 198Au from nasal mucous membrane into cerebrospinal fluid.
Acta Otolaryngol. 1970 Jul;70(1):58-61
PMID: 5457201
-
On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.
Brain. 1984 Jun;107 ( Pt 2):487-506
PMID: 6722513
-
Mechanism of nasal absorption of drugs. II: Absorption of L-tyrosine and the effect of structural modification on its absorption.
J Pharm Sci. 1985 Dec;74(12):1298-301
PMID: 4087196
-
The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.
Ann Neurol. 1985 Nov;18(5):537-43
PMID: 4073849
-
Pharmacokinetics of progesterone after its administration to ovariectomized rhesus monkeys by injection, infusion, or nasal spraying.
Proc Natl Acad Sci U S A. 1982 Jul;79(13):4185-9
PMID: 6955795
-
Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity.
J Pharm Pharmacol. 1991 Jun;43(6):449-51
PMID: 1681064